Further studies should focus on (1) the real rate and association (if there is any) of thromboembolic (both venous and arterial) events in COVID-19 patients and (2) identifying the patients who are at risk for thrombosis to determine the best preventive maneuvers (ie, aggressive anticoagulation therapies), thereby counterbalancing the risk of bleeding in such a high-risk population.